Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...

June 2026 - Clinical Trial and Case Study Results Highlight Diagnostic and Therapeutic Potential of SAR-bisPSMA Portfolio.

A man recently took to the internet to make sure everyone knows he’s a big fan of Flock Safety cameras. And if you get the ...

Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...

Reno, Nevada (UroToday.com) -- Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...

At 10 years, treatment with leuprorelin did not significantly improve OS (89.1% vs 88.9%) or disease-specific survival (98.6% vs 96.5%) compared with observation. The administration of leuprorelin ...

You breathe a little easier when the first test comes back with a number the doc calls “undetectable.” But, they don't have a bell for you to ring that soon, celebrating the “defeat” of the disease.

Prostate cancer is something that has been on Baltimore resident Jesse Bennett’s radar since he was in his early 40’s. That was when Jesse first had a PSA (prostate-specific antigen) level drawn, the ...

Dear Dr. Roach: I am a healthy 89-year-old United States Army veteran. In August 2017, I was diagnosed with advanced prostate cancer and was treated with Lupron and radiation. These treatments have ...

Last week we learned that former president Joe Biden’s last known screening test for prostate cancer was in 2014, presumably because the US Preventive Services Task Force advises against the routine ...